The performance of thiol-terminated PEG-paclitaxel-conjugated gold nanoparticles

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10217-10227

  Ding, Ya ^a   Zhou, Ying Ying ^a   Chen, Huan ^a   Geng, Dong Dong ^a   Wu, Dong Yan ^a   Hong, Jin ^a,b   Shen, Wen Bin ^a   Hang, Tai Jun ^a   Zhang, Can ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Double simultaneous stimulation; Drug release; Overall performance improvement; Paclitaxel conjugated gold nanoparticles; Target selection; Tumor therapeutic efficacy

Indexed keywords

DOUBLE SIMULTANEOUS STIMULATION; DRUG RELEASE; GOLD NANOPARTICLES; OVERALL PERFORMANCE IMPROVEMENT; TARGET SELECTION; THERAPEUTIC EFFICACY;

DISEASES; GOLD; METAL NANOPARTICLES; TUMORS;

LOADING;

GOLD NANOPARTICLE; MACROGOL; PACLITAXEL; THIOL DERIVATIVE;

ABSORPTION SPECTROSCOPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SIZE; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIVER CELL CARCINOMA; MALE; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; NONHUMAN; PERFORMANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; STEREOSPECIFICITY; THERAPY EFFECT; ZETA POTENTIAL;

MURINAE;

DOUBLE SIMULTANEOUS STIMULATION; DRUG RELEASE; OVERALL PERFORMANCE IMPROVEMENT; PACLITAXEL-CONJUGATED GOLD NANOPARTICLES; TARGET SELECTION; TUMOR THERAPEUTIC EFFICACY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; GOLD; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED ICR; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 84885382493     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.008     Document Type: Article

References (36)

1. Zhang Z., Mei L., Feng S.S. Paclitaxel drug delivery systems. Expert Opin Drug Deliv 2013, 10:325-340.
2. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Del 2004, 11:169-183.
3. Dykmana L., Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 2012, 41:2256-2282.
4. Paciotti G.F., Kingston D.G.I., Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Develop Res 2006, 67:47-54.
5. Tom R.T., Suryanarayanan V., Reddy P.G., Baskaran S., Pradeep T. Ciprofloxacin-protected gold nanoparticles. Langmuir 2004, 20:1909-1914.
6. Zhang X., Chibli H., Mielke R., Nadeau J. Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. Bioconjugate Chem 2011, 22:235-243.
7. Aryal S., Grailer J.J., Pilla S., Steeber D.A., Gong S. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. JMater Chem 2009, 19:7879-7884.
8. Wang F., Wang Y.C., Dou S., Xiong M.H., Sun T.M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
9. Chen H., Li B., Ren X., Li S., Ma Y., Cui S., et al. Multifunctional near-infrared-emitting nano-conjugates based on gold clusters for tumor imaging and therapy. Biomaterials 2012, 33:8461-8476.
10. Manju S., Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. JColloid Inter Sci 2012, 368:144-151.
11. Joshi P., Chakraborty S., Dey S., Shanker V., Ansari Z.A., Singh S.P., et al. Binding of chloroquine-conjugated gold nanoparticles with bovine serum albumin. JColloid Inter Sci 2001, 355:402-409.
12. Fleigea E., Quadirb M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Del Rev 2012, 64:866-884.
13. Cline E.N., Li M.H., Choi S.K., Herbstman J.F., Kaul N., Meyhöfer E., et al. Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action. Biomacromolecules 2013, 14:654-664.
14. Danhier F., Lecouturie N., Vroman B., JérÔme C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: Invitro and invivo evaluation. JControl Release 2009, 133:11-17.
15. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy invivo. Proc Natl Acad Sci U S A 2006, 103:6315-6320.
16. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
17. Chithrani B.D., Chan W.C.W. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7:1542-1550.
18. Cheng J.Y., Wang D.L., Xi J.F., Au L., Siekkinen A., Warsen A., et al. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett 2007, 7:1318-1322.
19. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advan Enzyme Regul 2001, 41:189-207.
20. Duncan R., Sat Y.N. Tumour targeting by enhanced permeability and retention (EPR) effect. Ann Oncol 1998, 9(Suppl.2):39-50.
21. Yue T., Zhang X. Cooperative effect in receptor-mediated endocytosis of multiple nanoparticles. ACS Nano 2012, 6:3196-3205.
22. Hong R., Han G., Fernández J.M., Kim B.J., Forbes N.S., Rotello V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. JAm Chem Soc 2006, 128:1078-1079.
23. Gibson J.D., Khanal B.P., Zubarev E.R. Paclitaxel-functionalized gold nanoparticles. JAm Chem Soc 2007, 129:11653-11661.
24. Zhang X.Q., Xu X., Lam R., Giljohann D., Ho D., Mirkin C.A. Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. ACS Nano 2011, 5:6962-6970.
25. Skwarczynski M., Hayashi Y., Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. JMed Chem 2006, 49:7253-7269.
26. Hwu J.R., Lin Y.S., Josephrajan T., Hsu M.H., Cheng F.Y., Yeh C.S., et al. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. JAm Chem Soc 2009, 131:66-68.
27. Mo R., Jin X., Li N., Ju C., Sun M., Zhang C., et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 2011, 32:4609-4620.
28. Li Y., Xu X., Shen Y., Qian C., Lu F., Guo S. Preparation and evaluation of copolymeric micelles with high paclitaxel contents and sustained drug release. Colloid Surf A 2013, 429:12-18.
29. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Delivery Rev 2001, 47:113-131.
30. Ding Y., Xia X.H., Zhai H.S. Reversible assembly and disassembly of gold nanoparticles directed by a zwitterionic polymer. Chem Eur J 2007, 13:4197-4302.
31. Ding Y., Gu G., Xia X.H. Cysteine-grafted chitosan-mediated gold nanoparticle assembly: from nanochains to microcubes. JMater Chem 2009, 19:795-799.
32. Mathew A.E., Mejillano M.R., Nath J.P., Himes R.H., Stella V.J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. JMed Chem 1992, 35:145-151.
33. Garea S.A., Ghebaur A. FT-IR spectroscopy and thermogravimetrical characterization of prodrugs based on different dendritic polymers and antitumoral drug. Mater Plast 2012, 49:1-4.
34. Ding Y., Xia X.H., Zhang C. Synthesis of metallic nanoparticles protected with N, N, N-trimethyl chitosan chloride via a relatively weak affinity. Nanotechnology 2006, 17:4156-4162.
35. Maxwell D.M., Brecht K.M., O'Neill B.L. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 1987, 39:35-42.
36. Maxwell D.M., Lenx D.F., Groff W.A., Kaminskis A., Froehlich H.L. The effects of blood flow and detoxification on invivo cholinesterase inhibition by soman in rats. Toxicol Appl Pharmacol 1987, 88:66-76.